




The burden of disease for children born alive with Turner syndrome—A European cohort study

Ann-Louise Rud Andersen¹ | Stine Kjaer Urhoj^{1,2} | Joachim Tan³ |
 Clara Caverro-Carbonell⁴ | Miriam Gatt⁵ | Mika Gissler^{6,7,8} | Kari Klungsoyr⁹ |
 Babak Khoshnood¹⁰ | Joan Morris³  | Amanda J. Neville¹¹ | Anna Pierini¹² |
 Ieuan Scanlon¹³ | Hermien E. K. de Walle¹⁴ | Diana Wellesley¹⁵ |
 Ester Garne¹  | Maria Loane¹⁶ 

¹Department of Paediatrics and Adolescent Medicine, Lillebaelt Hospital University Hospital of Southern Denmark, Kolding, Denmark

²Section of Epidemiology, Department of Public Health, University of Copenhagen, Copenhagen, Denmark

³Population Health Research Institute, St George's University of London, London, UK

⁴Rare Diseases Research Unit, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (UVEG-FISABIO), Valencia, Spain

⁵Malta Congenital Anomalies Register, Directorate for Health Information and Research, Tal-Pietà, Malta

⁶Department of Knowledge Brokers, THL Finnish Institute for Health and Welfare, Helsinki, Finland

⁷Region Stockholm, Academic Primary Health Care Centre, Stockholm, Sweden

⁸Karolinska Institute, Department of Molecular Medicine and Surgery, Stockholm, Sweden

⁹Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway

¹⁰INSERM-INRA, Université de Paris, Center of Research in Epidemiology and Statistics (CRESS), Paris, France

¹¹Emilia Romagna Registry of Birth Defects and Center for Clinical and Epidemiological Research, University of Ferrara and Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy

¹²Unit of Epidemiology of Rare Diseases and Congenital Anomalies, Institute of Clinical Physiology, National Research Council, Pisa, Italy

¹³Public Health Wales, Swansea, UK

¹⁴University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, the Netherlands

¹⁵Clinical Genetics, University of Southampton and Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK

¹⁶Faculty of Life and Health Sciences, Ulster University, Northern Ireland, UK

Correspondence

Ester Garne, Department of Paediatrics and Adolescent Medicine, Lillebaelt Hospital, University Hospital of Southern Denmark, Kolding, Denmark.
 Email: ester.garne@rsyd.dk

Funding information

Horizon 2020 Framework Programme, Grant/Award Number: 733001

Abstract

Background: Turner syndrome is a rare congenital anomaly caused by complete or partial X chromosome monosomy that may affect mortality and morbidity in childhood.

Methods: This population-based data-linkage cohort study, as part of the EURO-linkCAT project, investigated mortality and morbidity for the first 5 years of life for liveborn European children diagnosed with Turner syndrome. Thirteen population-based registries in 10 countries from the European surveillance of congenital anomalies (EUROCAT) network participated. Data on children born 1995–2014 and diagnosed with Turner syndrome were linked to mortality,

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2023 The Authors. *Birth Defects Research* published by Wiley Periodicals LLC.

hospital and prescription records. Children with any congenital anomaly and children without a congenital anomaly were included for comparison on morbidity.

Results: Out of a population of 5.8 million livebirths 404 were diagnosed with Turner syndrome prenatally or in infancy and 95.5% survived to their fifth birthday. During the first year of life 72.3% (95% CI 59.5;81.6) of children with Turner syndrome were hospitalized, the median length of stay was 5.6 days (95% CI 3.5;7.7) and 18.7% (95% CI 13.9;23.9) underwent surgery. After the first year of life hospitalizations and length of stay decreased but more children underwent surgery (30.8% [95% CI 17.6;44.7]). In the first 5 years the percentage of children with Turner syndrome having a prescription for antibiotics was 12%–20% per year and increased with the age of child.

Conclusions: In the first year of life, the burden of disease was relatively high for children with Turner syndrome. The outlook is more positive beyond the first year, though overall morbidity still exceeded that of children without congenital anomalies.

KEYWORDS

congenital anomaly, morbidity, survival, Turner syndrome

1 | INTRODUCTION

Turner syndrome is a sex chromosomal aneuploidy (45 X or 45 X mosaicism) in females, which may be diagnosed prenatally, after birth or later in life (Gravholt et al., 2019; Yesilkaya et al., 2015). It is primarily associated with physical symptoms, such as associated congenital anomalies, reduced height, lack of pubertal development and hence infertility (Gravholt, 2004; Gravholt et al., 2019; Yesilkaya et al., 2015).

The prevalence is estimated to be 5 per 10,000 live born females with a wide range from 2.5 to 21 per 10,000 females depending on method of testing and whether only children are included or also teenagers and adults and estimated number of affected spontaneously aborted fetuses (Gravholt, 2004; Hook & Warburton, 1983; Mortensen et al., 2012; Stochholm et al., 2006). Around half of the diagnosed cases are monosomy 45,X and the rest have mosaicism or other karyotypes (Gravholt et al., 2019; Yesilkaya et al., 2015). Studies have shown that 1 out of 10 are diagnosed prenatally with amniocentesis or chorion villus sampling after abnormal ultrasound findings such as hydrops fetalis or cystic hygroma or incidentally during the screening for other more severe chromosomal anomalies as Down syndrome (Gravholt et al., 2017; Swauger et al., 2021). The age of diagnosis ranges from 0 to 85 years for the different karyotypes as reported by Stochholm et al. (2006), but Swauger et al. (2021) reported a median age of diagnosis with a range from 4 to 18 years, and for

those diagnosed after the first year of life the median age of diagnosis was 9.3 years.

Termination of pregnancy after prenatal diagnosis (TOPFA) may be offered to the pregnant woman and in some studies, termination was chosen in 70%–80% of the prenatally diagnosed cases (Christian et al., 2000; Stochholm et al., 2006). Data from the European Surveillance of Congenital Anomalies (EUROCAT, n.d.) have shown a prevalence of TOPFA for Turner syndrome at 1.59 (95% CI 1.52;1.67) per 10,000 births in 1995–2014 corresponding to 63% of the cases with Turner syndrome reported to EUROCAT with many of these also diagnosed with severe hydrops or a significant congenital heart defect (EUROCAT website 2022).

Turner syndrome is associated with increased mortality (Schoemaker et al., 2008) and increased morbidity (Gravholt et al., 1998; Yesilkaya et al., 2015) particularly due to associated cardiac and renal anomalies as well as endocrine disorders (Gravholt et al., 2017; Mortensen et al., 2012). Previous studies were often based on small sample sizes and were not including the general burden of disease compared to the background population. Studies describing survival and morbidity of young children diagnosed with Turner syndrome are limited. Information on mortality and morbidity in childhood is important for counseling of parents after a prenatal diagnosis of Turner syndrome.

This study was part of the EUROLINKCAT project, a European population-based record-linkage cohort study, that used the EUROCAT infrastructure to establish

TABLE 1 Overview of the contributing EUROlinkCAT registries for which data were available for analyses for children with Turner syndrome.

Registry	Birth years	Total births	Data on survival	Data on hospital stays	Data on surgeries	Data on antibiotic prescriptions
Denmark, Funen	1995–2014	100,119	Yes	Yes	Yes	Yes
Finland	1995–2014	1,169,172	Yes	Yes	Yes	Yes
France, Paris	1995–2014	592,373	Yes	No	No	No
Italy, Emilia Romagna	2008–2014	281,309	Yes	Yes	Yes	Yes
Italy, Tuscany	2005–2014	299,089	Yes	Yes	Yes	Yes
Malta	2005–2014	40,737	Yes	No	No	No
Netherlands, Northern	2005–2010 2013–2014	139,269	Yes	Yes	No	No
Norway	1999–2014	948,013	Yes	No	No	No
Spain, Valencian Region	2007–2014	401,231	Yes	Yes	Yes	Yes
UK, East Midland (EM) & Southern Yorkshire (SY)	2003–2012	712,960	Yes	Yes	Yes	No
UK, Thames Valley	2005–2013	268,974	Yes	Yes	Yes	No
UK, Wales	1998–2014	566,470	Yes	Yes	Yes	Yes
UK, Wessex	2004–2014	299,644	Yes	Yes	Yes	No
Total		5,819,360	13 registries	10 registries	9 registries	6 registries

standardized datasets containing information about survival and morbidity for children up to 10 years of age with major congenital anomalies (Morris et al., 2021). The aim of this study was to estimate the survival of live-born children with Turner syndrome up to age 5 years and to examine morbidity measured as hospitalizations, length of stay in hospital, surgery and antibiotic prescriptions for children diagnosed prenatally or in infancy with Turner syndrome compared to all children with a congenital anomaly and to reference children.

2 | METHODS

This is a European, population-based data-linkage cohort study using routinely collected data from mortality databases and hospital discharge databases. The study

includes data from 13 EUROCAT registries (national and regional) in 10 countries, see Table 1.

2.1 | Population

The inclusion criteria were all children born alive between 1995 and 2004 in the geographic areas covered by the EUROCAT registries and diagnosed with Turner syndrome prenatally or in infancy. The EUROCAT subgroup of Turner syndrome is based on the ICD9 code 7586 except 75,868 and the ICD10 code Q96. The registries include cases with confirmed karyotype anomalies only. The ICD9 and ICD10 codes for all liveborn children with Turner syndrome were checked in the EUROCAT central database for the same registries and birth years as included in this study, except for Finland. The data

extract showed that 35% had a code for karyotype 45X, 54% had a code for other Turner karyotypes including mosaicism and 11% had an unspecified code for Turner syndrome.

For registries included in the analyses of morbidity, we also included data on all children born with major congenital anomalies defined by EUROCAT as “All anomalies”. All children without a congenital anomaly born in the same birth years and from the same geographical area covered by the registry were included as a reference population (reference children) (Morris et al., 2021). These two comparison groups included both girls and boys. The registry in Tuscany used a 10% random sample of their population as reference children and the Northern Netherlands registry used a random sample of 20% of their population for each birth year as reference children. For the three English registries information on reference children was not available.

All children in the study were followed from birth to their 10th birthday or to the end of 2015 whichever came first, thus all children had at least 1 year of follow-up.

2.2 | Data on survival

Data on survival were obtained for children diagnosed with Turner syndrome by linkage to vital statistics and death certificates and were available for 13 registries in 10 countries. The mortality rate for all liveborn children across Europe were obtained from the statistical office of the European Union (EU), EUROSTAT and converted to a survival rate for comparison of the survival for children diagnosed with Turner syndrome.

2.3 | Data on hospitalization

Data on hospitalizations and surgical procedures were obtained for all three groups of children by electronic linkage to the hospital databases used in the regions and countries. For the morbidity study, the linkage success was 97% for children with congenital anomalies and 95% for reference children. Further details of the linkage methods used in the EUROlinkCAT study have been published earlier (Morris et al., 2021; Urhoj et al., 2022). Data on hospitalization for children with Turner syndrome were available for 10 registries (Table 1). For 6 of the 10 registries the hospital databases covered hospital stays in the whole country. For Wales, hospital stays in England were included. For the Valencian Region in Spain and Emilia Romagna in Italy, the hospital databases covered the same region as the EUROCAT registry. Data on hospitalization for reference children and children with any congenital anomaly were obtained from

the EUROlinkCAT study on hospitalizations (Urhoj et al., 2022). Data included length of hospital stays measured as the number of days in hospital per year and for term born children hospital stays of 10 days or more.

2.4 | Data on surgeries

Data on surgical procedures for all three groups of children were available for eight registries (Table 1). Surgical procedures were coded according to the coding systems used in the national health systems. Italy and Spain used ICD-9-CM (the International Classification of Diseases, 9th revision-Clinical Modification) for the study period, England and Wales used OPCS-4 (Classification of Interventions and Procedures) and Finland and Denmark used national adaptations of NCSP (NOMESCO Classification of Surgical Procedures). Three pediatricians from two European countries independently reviewed all the codes from the extensive lists of surgery and procedure codes from the six countries with the three different coding systems and reached consensus on which codes defined surgeries. The study variable “Any surgery” was included.

2.5 | Data on antibiotic prescriptions

Data on the number of antibiotics prescriptions were obtained by linking to electronic prescription databases in six registries. We included antibiotics codes beginning with J01 as defined by the WHO Anatomical Therapeutic Chemical (ATC) classification system. Data were included from the year 2000 or the first birth year included in the study by each registry up to the end of 2015. We estimated the proportion of children with Turner syndrome who received at least one antibiotic prescription up to age 5 years.

2.6 | Statistical analysis

A common data model was developed to standardize the variables from the hospital and prescription databases. This enabled all registries to run centrally written syntax scripts in Stata version 13 for linkage quality checks and analyses. The aggregated tables and analytic results produced were then sent to a Central Results Repository at Ulster University. No individual case data were shared.

All analyses were performed separately for two age groups: <1 year (0–364 days) and 1–4 years.

The number of days spent in hospital was calculated as using the day of admission and the day of discharge. If the date of admission and discharge occurred on the

same day, the length of stay was determined to be 0.5 days. Quantile estimation methods were used to obtain pooled estimates of the median number of days spent in hospital per year for those with at least one hospital admission in a random effects meta-analysis using the “metamedian” package in R, version 4.0.3.

In each registry, the percentages of children hospitalized and with surgeries within each age group were calculated using Kaplan Meier (KM) survival analyses to allow for the censoring on December 31, 2015, death or emigration. Pooled estimates of the percentage hospitalized and with surgery were calculated in random effects meta-analysis using the $\ln(-\ln(S(t)))$ transformation in STATA version 15. As only few children with Turner syndrome had extended hospital stays, the percentage with extended stays was calculated by summing the totals ignoring registry or censoring and the Wilson confidence interval for proportions was used.

3 | RESULTS

Between 1995 and 2014, 404 children were born and diagnosed with Turner syndrome prenatally or during

infancy within the study areas. Total number of livebirths in the study areas was 5,819,360 giving a livebirth prevalence of Turner syndrome of 0.69 per 10,000 births (Table 1).


Eighteen of the 404 children diagnosed with Turner syndrome died within the first 5 years of life resulting in an overall survival rate of 95.5% at 5 years of age. There were less than three deaths after the first year of life.

For the morbidity analyses 300 children with Turner syndrome were included in the analyses of hospitalization and 260 children were included in the analyses of surgeries. During the first year after birth 72.3% (95% CI 59.5;81.6) of the children with Turner syndrome were admitted to hospital (Table 2). The proportion of children admitted to hospital at ages 1–4 years decreased as also occurred in the reference children. The median length of stay was 5.6 days (95% CI 3.5;7.7) in the first year and 19.4% (95% CI 14.7;25.2) of those born at term had a hospital stay of more than 10 days during the first year. For comparison with children with any congenital anomaly and reference children see Table 2 and Figure 1a–c.


During the first year 18.7% (95% CI 13.9;23.9) of children with Turner syndrome had surgery performed increasing to 30.8% (95% CI 17.6;44.7) of the children at

TABLE 2 Data on hospitalization of children with Turner syndrome, children with any congenital anomaly and reference children in two age groups (<1 year and 1–4 years).


Age group	Number of children	Number of children admitted to hospital	% of children with any hospital admission (95% CI)	Median length of stay in days (95% CI)	Number of children born at term	Number of children with a hospital stay ≥10 days	% of children with a hospital stay ≥10 days (95% CI)
<1 year							
Children with Turner syndrome	300	213	72.3 (59.5;81.6)	5.6 (3.5;7.7)	216	42	19.4 (14.7;25.2)
Children with any congenital anomaly	99,414	73,080	84.9 (78.6;89.5)	7.9 (7.0;8.8)	76,295	14,625	23.9 (19.5;28.5)
Reference children	2,016,042	540,046	31.0 (25.7;36.5)	3.0 (2.3;3.7)	1,825,115	17,295	1.2 (0.9;1.7)
1–4 years							
Children with Turner syndrome	291	169	54.6 (39.0;67.8)	0.5 (0.3;0.6)	210	12	5.7 (3.3;9.7)
Children with any congenital anomaly	94,555	50,829	56.2 (51.1;61.0)	1.0 (0.7;1.2)	73,793	3302	5.4 (4.8;6.1)
Reference children	1,995,699	498,420	24.6 (18.8; 31.0)	0.4 (0.2;0.5)	1,803,378	7973	0.6 (0.5;0.8)




(a) Percentage of children <1 year with any hospital admission (95% CI)



(b) Median length of stay in days for children <1 year of age (95% CI)



(c) Percentage of children with a hospital stay ≥10 days (95% CI)



(d) Percentage of children <1 year with any surgery (95% CI)

FIGURE 1 Comparison of morbidity for children diagnosed with Turner syndrome, children with any congenital anomaly and reference children in the age group <1 year presented for (a) the percentage of children with any hospital admission (95% CI), (b) median length of stay in days (95% CI), (c) percentage of children with a hospital stay ≥10 days (95% CI), (d) percentage of children with any surgery (95% CI).

age 1–4 years. The median number of surgeries per child in the first year was 1.0 (95% CI 0.98;1.02) and the median age of first surgery was 4.9 weeks (95% CI 0.7;9) for surgeries performed in the first year of life (Table 3 and Figure 1d).

Prescription data were available from six registries for the period 2000–2015 and included 143 children with Turner syndrome. Figure 2 shows the percentage of these children who had a prescription for any antibiotics, by age of the child. The average percentage of antibiotic prescriptions increased with age. The proportion of children

aged 4–5 years who had a prescription for antibiotics was 19.8%, compared to 11.5% for children aged <1 year.


4 | DISCUSSION

This study is the first population-based multi-center study to evaluate the burden of disease in terms of survival, hospitalization, surgery and prescriptions for antibiotic prescriptions for the first 5 years of life in children diagnosed with Turner syndrome prenatally or in

TABLE 3 Data on surgeries for children with Turner syndrome, children with any congenital anomaly and reference children in two age groups (<1 year and 1–4 years).

Age group	Number of children	Number children with any surgery	% of children with any surgery (95% CI)	Median number of surgeries per child (95% CI)	Median age of first surgery in weeks (95% CI)
<1 year					
Children with Turner syndrome	260	47	18.7 (13.9;23.9)	1.0 (0.98–1.02)	4.9 (0.7;9)
Children with any congenital anomaly	91,504	29,616	37.8 (32.3;43.22)	1.78 (1.49;2.1)	11.2 (9.5;12.9)
Reference children	1,960,272	18,057	0.79 (0.55;1.11)	1 (0.99;1.0)	17.1 (11.9;24.3)
1–4 years					
Children with Turner syndrome	251	86	30.8 (17.6;44.7)	1.6 (0.8;2.4)	138.6 (103.1;173.9)
Children with any congenital anomaly	87,129	26,427	34.5 (31.2;37.9)	1.78 (1.49;1.07)	94.4 (86.7;102.0)
Reference children	1,935,199	141,465	6.25 (4.01;9.16)	1 (0.99;1.00)	167 (147.5;186.5)

FIGURE 2 Proportion of children with Turner syndrome who had an antibiotic prescription by age. Numbers are combined for all registries. Each child may appear in more than one age group.



infancy. The livebirth prevalence was 0.69 per 10,000 live births which is in line with the finding in other studies of 10% diagnosed prenatally and in infancy (Swauger et al., 2021). Our results can be applied to children diagnosed prenatally and shortly after birth with any of the

karyotypes associated with Turner syndrome. Studies have described an association between the genetic expression, phenotypic expression, and the severity of comorbidities (Cameron-Pimblett et al., 2017; Tuke et al., 2019). In this study it was not possible to

distinguish the different karyotypes as they were analyzed as one group.

In 2009 the infant mortality rate among all live born infants across the EU was 4.2 deaths per 1000 live births (EUROSTAT website, 2021). This study showed a survival rate within the first 5 years of life for children with Turner syndrome at 95.5% with the majority of deaths in the first year, which gives a 10-fold higher mortality in infancy when compared to all liveborn children in EU. A British cohort study reported a three-fold higher overall mortality than the general population and the expected life span for adults diagnosed with Turner syndrome was reduced by 8–10 years (Schoemaker et al., 2008).

The overall morbidity for children with Turner syndrome was higher than for reference children and more comparable to children with any congenital anomaly. For both reference children and children diagnosed with Turner syndrome morbidity decreased after the first year of life. Our results are consistent with a higher burden of disease in early childhood for children with Turner syndrome. This is a result of associated comorbidities such as congenital heart defects and renal anomalies (Mortensen et al., 2012; Yesilkaya et al., 2015). Diagnosis such as coarctation of the aorta, bicuspid aortic valves and other aortic arch anomalies are estimated to affect 23%–50% of the children with Turner syndrome and will increase the proportion of hospitalization and the need for surgery (Gravholt et al., 2017; Mortensen et al., 2012; Urhoj et al., 2022). Children with Turner syndrome are more likely to be born moderate preterm and/or small for gestational age (Hagman et al., 2010) which also will increase the length of stay in hospital in the first year due to feeding problems. Another known issue for females diagnosed with Turner syndrome is short stature (Gravholt et al., 2019). During childhood growth hormone treatments are initiated to improve the final height. This requires continuing health care visits, but usually not hospitalizations and therefore most likely not contributing to the burden of disease in terms of hospitalization analyzed in this study (Bondy, 2007; Gravholt et al., 2017).

Our study showed that approximately 2 out of 10 children with Turner syndrome had surgery performed within the first year of life, increasing to 3 out of 10 at ages 1–4 years. We had no available data regarding the type of surgery, but surgical procedures are frequently required for the congenital heart defects, especially coarctation of the aorta and aortic arch anomalies associated with Turner syndrome. Alam et al. (2021) found an average age at the first surgery of 1 month for females <21 years with Turner syndrome and an associated congenital heart defect, which corresponds to the median

age at first surgery of 4.9 weeks found in this study. Some of the surgical procedures in children with additional Y-chromosome material may be due to the recommended gonadectomy due to the risk of cancer, although this may be done after 5 years of age (Gravholt et al., 2017). Otological disorders may as well contribute to the percentage of children who undergo surgery as Lim et al. found that 18.9% of the girls with Turner syndrome had insertion of tympanostomy tubes and/or myringotomy performed at 0–5 years of age (Lim et al., 2020). Sometimes these procedures are performed as an outpatient visit, but due to the increased anesthetic risks that may be present for children with Turner syndrome and associated comorbidities, especially the cardiac anomalies, these surgeries are more likely to take place in hospitals (Liese et al., 2014).

We found that 20% of children with Turner syndrome aged 4–5 years received antibiotic prescription. These children frequently suffer from recurrent acute otitis media, tympanic membrane perforation and cholesteatoma (Bois et al., 2018; Lim et al., 2020). The study from UK found that within a period of 1 year 24% of children with Turner syndrome experienced recurrent otitis media at 0–5 years compared to <2% with three or more episodes of acute otitis media in the general pediatric population before 6 years of age (Lim et al., 2020). Children with Turner syndrome also has an increased risk of renal anomalies and therefore also increased risk of urinary tract infections (Yesilkaya et al., 2015).

Children with Turner syndrome diagnosed prenatally or in infancy may represent the most severe cases with early symptoms prenatally as lymphedema or webbed neck as well as those found incidental with prenatal testing (Swauger et al., 2021). The overall median age at diagnosis found by Schoemaker et al. was 14.5 years and it has been estimated that around 20% of the children diagnosed between 11 and 18 years due to short stature or lack of pubertal development may not show any symptoms earlier in childhood (Schoemaker et al., 2008; Swauger et al., 2021). It may be hard to distinguish these children from unaffected children and they will probably have a survival rate closer to the overall infant and childhood mortality rate as well as hospital admissions and surgeries more similar to the reference children in this study.

It is a limitation of the study that the two comparison groups included all children and not girls only as girls are less likely to be in hospital. A study from Australia found that boys were more likely to be admitted to hospital than girls for both the group of children with major congenital anomalies and for the children without congenital anomalies (Colver & Bower, 2009).

The decision to continue or terminate the pregnancy after a prenatally diagnosis of Turner syndrome may be

very difficult (Hermann et al., 2019; Jeon et al., 2012). Unbiased information about the prognosis and potential benefit of early diagnosis is important to discuss before taking a decision (Holm et al., 2021; Jaramillo et al., 2019; Wasserman & Asch, 2012). Results from this study will be useful in the counseling of parents after a prenatal diagnosis. Early diagnosis and knowledge about the risk of increased morbidity and lower first year survival is important for the physicians when counseling a couple expecting or having a child with Turner syndrome (Gravholt et al., 2017). This knowledge provides an opportunity to plan for a multispecialty team of health care providers to assist the family and plan the best possible care for the child and the family which enables early therapeutic intervention and managing comorbidities.

5 | CONCLUSION

The overall survival rate for live born children diagnosed early with Turner syndrome was 95.5% for the first 5 years of life. Children with Turner syndrome were more often hospitalized, they had longer stay and a higher proportion underwent surgery compared to children without congenital anomalies for the first 5 years of life. Antibiotic prescriptions increased with the age of child. The burden of disease for children diagnosed with Turner syndrome is rather high during the first year but improves later in childhood. Our results can be applied to the children diagnosed prenatally and shortly after birth.

AUTHOR CONTRIBUTIONS

Joan Morris, Maria Loane and Ester Garne designed the EUROLINKCAT study and obtained funding. Ann-Louise Rud Andersen wrote the protocol for this study. Ann-Louise Rud Andersen, Stine Kjaer Urhoj and Joachim Tan analyzed the data. Amanda J. Neville, Anna Pierini, Babak Khoshnood, Clara Caverro-Carbonell, Diana Wellesley, Hermien E. K. de Walle, Kari Klungsoyr, Miriam Gatt, Mika Gissler and Ester Garne contributed with data from their EUROCAT registries. Maria Loane, Ieuan Scanlon and Stine Kjaer Urhoj performed the standardization of the variables. Joan Morris supervised the analysis scripts. Ann-Louise Rud Andersen wrote the first draft of the manuscript. All authors reviewed and revised the manuscript.

ACKNOWLEDGMENTS

Thanks to Annie Perraud from the JRC-EUROCAT Central Registry, European Commission, Joint Research Centre (JRC), Ispra, Italy, for providing data on the distribution of the codes for Turner syndrome in the EUROCAT central database.

FUNDING INFORMATION

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 733001. The funders had no role in the study.

CONFLICT OF INTEREST STATEMENT

The authors have no relevant financial or non-financial interests to disclose.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the participating registries of congenital anomalies, but restrictions apply to the availability of these data, which were used under license for the current study. These data are available for scientifically valid requests and with permission of the participating registries of congenital anomalies. To apply for the data please contact the corresponding author.

ORCID

Joan Morris  <https://orcid.org/0000-0002-7164-612X>
 Ester Garne  <https://orcid.org/0000-0003-0430-2594>
 Maria Loane  <https://orcid.org/0000-0002-1206-3637>

REFERENCES

- Alam, S., Claxton, J. S., Mortillo, M., Sassis, L., Kefala-Karli, P., Silberbach, M., Kochilas, L., & Wechsler, S. B. (2021). Thirty-year survival after cardiac surgery for patients with Turner syndrome. *The Journal of Pediatrics*, 239, 187–192.e1.
- Bois, E., Nassar, M., Zenaty, D., Leger, J., Van Den Abbeele, T., & Teissier, N. (2018). Otologic disorders in Turner syndrome. *European Annals of Otorhinolaryngology, Head and Neck Diseases*, 135(1), 21–24.
- Bondy, C. A. (2007). Care of girls and women with Turner syndrome: A guideline of the Turner syndrome study group. *The Journal of Clinical Endocrinology & Metabolism*, 92(1), 10–25.
- Cameron-Pimblett, A., La Rosa, C., King, T. F. J., Davies, M. C., & Conway, G. S. (2017). The Turner syndrome life course project: Karyotype-phenotype analyses across the lifespan. *Clinical Endocrinology*, 87(5), 532–538.
- Christian, S. M., Koehn, D., Pillay, R., MacDougall, A., & Wilson, R. D. (2000). Parental decisions following prenatal diagnosis of sex chromosome aneuploidy: A trend over time. *Prenatal Diagnosis*, 20, 37–40.
- Colver, L., & Bower, C. (2009). A retrospective population-based study of childhood hospital admissions with record linkage to a birth defect registry. *BMC Pediatrics*, 9, 32.
- EUROCAT. (n.d.). Prevalence charts and tables. European Platform on Rare Disease Registration [updated 03/06/2022; cited 2022/12/06]. https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-data/prevalence_en
- EUROSTAT. (2021). Mortality and life expectancy statistics – Infant mortality [updated 2021 May; cited 2022 February]. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Mortality_and_life_expectancy_statistics

- Gravholt, C. H. (2004). Epidemiological, endocrine and metabolic features in Turner syndrome. *European Journal of Endocrinology*, *150*, 657–687.
- Gravholt, C. H., Andersen, N. H., Conway, G. S., Dekkers, O. M., Geffner, M. E., Klein, K. O., Lin, A. E., Mauras, N., Quigley, C. A., Rubin, K., Sandberg, D. E., Sas, T. C. J., Silberbach, M., Söderström-Anttila, V., Stochholm, K., van Alfen-van der Velden, J. A., Woelfle, J., Backeljauw, P. F., & International Turner Syndrome Consensus Group. (2017). Clinical practice guidelines for the care of girls and women with Turner syndrome: Proceedings from the 2016 Cincinnati international Turner syndrome meeting. *European Journal of Endocrinology*, *177*(3), G1–G70.
- Gravholt, C. H., Juul, S., Naeraa, R. W., & Hansen, J. (1998). Morbidity in Turner syndrome. *Journal of Clinical Epidemiology*, *51*(2), 147–158.
- Gravholt, C. H., Viuff, M. H., Brun, S., Stochholm, K., & Andersen, N. H. (2019). Turner syndrome: Mechanisms and management. *Nature Reviews. Endocrinology*, *15*(10), 601–614.
- Hagman, A., Wennerholm, U.-B., Källen, K., Barrenäs, M.-L., Landin-Wilhelmsen, K., Hanson, C., & Bryman, I. (2010). Women who gave births to girls with Turner syndrome: Maternal and neonatal characteristics. *Human Reproduction*, *25*, 1553–1560.
- Hermann, M., Khoshnood, B., Anselem, O., Bouvattier, C., Coussement, A., Brisset, S., Benachi, A., & Tsatsaris, V. (2019). Lack of consensus in the choice of termination of pregnancy for Turner syndrome in France. *BMC Health Services Research*, *19*(1), 994.
- Holm, K. G., Neville, A. J., Pierini, A., Bielenska, A. L., Jamry-Dziurla, A., Caverro-Carbonell, C., Garne, E., & Clemensen, J. (2021). The voice of parents of children with a congenital anomaly – A EUROlinkCAT study. *Frontiers in Pediatrics*, *9*, 654883.
- Hook, E. B., & Warburton, D. (1983). The distribution of chromosomal aenotypes Associated with Turner's syndrome: Livebirth prevalence rates and evidence for diminished fetal mortality and severity in genotypes associated with structural X abnormalities or mosaicism. *Human Genetics*, *64*, 25–27.
- Jaramillo, C., Nyquist, C., Riggan, K. A., Egginton, J., Phelan, S., & Allyse, M. (2019). Delivering the diagnosis of sex chromosome aneuploidy: Experiences and preferences of parents and individuals. *Clinical Pediatrics*, *58*(3), 336–342.
- Jeon, K. C., Chen, L. S., & Goodson, P. (2012). Decision to abort after a prenatal diagnosis of sex chromosome abnormality: A systematic review of the literature. *Genetics in Medicine*, *14*(1), 27–38.
- Liese, J. G., Silfverdal, S. A., Giaquinto, C., Carmona, A., Larcombe, J. H., Garcia-Sicilia, J., Fuat, A., Garcés-Sánchez, M., Basanta, M. L. A., Hiraldo, E. M., Cantarutti, L., Kroeniger, W., Vollmar, J., Holl, K., Pirçon, J. Y., & Rosenlund, M. R. (2014). Incidence and clinical presentation of acute otitis media in children aged <6 years in European medical practices. *Epidemiology and Infection*, *142*(8), 1778–1788.
- Lim, D., Hassani, S., Lupton, K., Gault, E. J., Wynne, D., Clement, W., Kubba, H., Mason, A., & Donaldson, M. (2020). Prevalence, risk factors and management strategies for otological problems in girls with Turner syndrome. *Acta Paediatrica*, *109*(10), 2075–2083.
- Morris, J. K., Garne, E., Loane, M., Barisic, I., Densem, J., Latos-Bielenska, A., Neville, A., Pierini, A., Rankin, J., Rissmann, A., de Walle, H., Tan, J., Given, J. E., Claridge, H., & EUROlinkCAT Consortium. (2021). EUROlinkCAT protocol for a European population-based data linkage study investigating the survival, morbidity and education of children with congenital anomalies. *BMJ Open*, *11*(6), e047859.
- Mortensen, K. H., Andersen, N. H., & Gravholt, C. H. (2012). Cardiovascular phenotype in Turner syndrome – Integrating cardiology, genetics, and endocrinology. *Endocrine Reviews*, *33*(5), 677–714.
- Schoemaker, M. J., Swerdlow, A. J., Higgins, C. D., Wright, A. F., Jacobs, P. A., & United Kingdom Clinical Cytogenetics Group. (2008). Mortality in women with Turner syndrome in Great Britain: A national cohort study. *The Journal of Clinical Endocrinology and Metabolism*, *93*(12), 4735–4742.
- Stochholm, K., Juul, S., Juel, K., Naeraa, R. W., & Gravholt, C. H. (2006). Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. *The Journal of Clinical Endocrinology and Metabolism*, *91*(10), 3897–3902.
- Swauger, S., Backeljauw, P., Hornung, L., Shafer, J., Casnellie, L., & Gutmark-Little, I. (2021). Age at and indication for diagnosis of Turner syndrome in the pediatric population. *American Journal of Medical Genetics. Part A*, *185*(11), 3411–3417.
- Tuke, M. A., Ruth, K. S., Wood, A. R., Beaumont, R. N., Tyrrell, J., Jones, S. E., Yaghootkar, H., Turner, C. L. S., Donohoe, M. E., Brooke, A. M., Collinson, M. N., Freathy, R. M., Weedon, M. N., Frayling, T. M., & Murray, A. (2019). Mosaic Turner syndrome shows reduced penetrance in an adult population study. *Genetics in Medicine*, *21*(4), 877–886.
- Urhoj, S. K., Tan, J., Morris, J. K., Given, J., Astolfi, A., Baldacci, S., Barisic, I., Brigden, J., Caverro-Carbonell, C., Evans, H., Gissler, M., Heino, A., Jordan, S., Lutke, R., Odak, L., Puccini, A., Santoro, M., Scanlon, I., de Walle, H. E. K., ... Garne, E. (2022). Hospital length of stay among children with and without congenital anomalies across 11 European regions – A population-based data linkage study. *PLoS One*, *17*(7), e0269874.
- Wasserman, D., & Asch, A. (2012). Reproductive medicine and Turner syndrome: Ethical issues. *Fertility and Sterility*, *98*(4), 792–796.
- Yesilkaya, E., Bereket, A., Darendeliler, F., Bas, F., Poyrazoglu, S., Aydin, B. K., Darcan, Ş., DüNDAR, B., Büyükinan, M., Kara, C., Sarı, E., Adal, E., Akıncı, A., Atabek, M. E., Demirel, F., Çelik, N., Özkan, B., Özhan, B., Orbak, Z., ... Bondy, C. (2015). Turner syndrome and associated problems in Turkish children: A multicenter study. *Journal of Clinical Research in Pediatric Endocrinology*, *7*(1), 27–36.

How to cite this article: Andersen, A.-L. R., Urhoj, S. K., Tan, J., Caverro-Carbonell, C., Gatt, M., Gissler, M., Klungsoyr, K., Khoshnood, B., Morris, J., Neville, A. J., Pierini, A., Scanlon, I., de Walle, H. E. K., Wellesley, D., Garne, E., & Loane, M. (2023). The burden of disease for children born alive with Turner syndrome—A European cohort study. *Birth Defects Research*, 1–10. <https://doi.org/10.1002/bdr2.2222>